Tempest Therapeutics’ (TPST) Buy Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of Tempest Therapeutics (NASDAQ:TPST) in a research note published on Thursday, Benzinga reports. They currently have a $47.00 price target on the stock.

Separately, Piper Sandler reiterated an overweight rating and issued a $8.00 target price on shares of Tempest Therapeutics in a research report on Friday, June 21st. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, the company presently has a consensus rating of Buy and an average price target of $20.75.

Tempest Therapeutics Price Performance

TPST stock opened at $1.03 on Thursday. The company has a quick ratio of 2.17, a current ratio of 2.17 and a debt-to-equity ratio of 0.12. Tempest Therapeutics has a 52-week low of $0.92 and a 52-week high of $9.00. The stock’s 50 day moving average is $1.33 and its two-hundred day moving average is $2.41. The company has a market capitalization of $22.77 million, a PE ratio of -0.60 and a beta of -1.86.

Tempest Therapeutics (NASDAQ:TPST) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.42) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.47) by $0.05. Analysts predict that Tempest Therapeutics will post -1.43 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, major shareholder Versant Venture Capital Vi, L. sold 400,000 shares of Tempest Therapeutics stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $1.35, for a total value of $540,000.00. Following the sale, the insider now directly owns 597,940 shares in the company, valued at $807,219. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 3.27% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Tempest Therapeutics

A hedge fund recently bought a new stake in Tempest Therapeutics stock. Dimensional Fund Advisors LP bought a new stake in Tempest Therapeutics, Inc. (NASDAQ:TPST) during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 25,084 shares of the company’s stock, valued at approximately $55,000. Dimensional Fund Advisors LP owned 0.11% of Tempest Therapeutics at the end of the most recent reporting period. 22.52% of the stock is currently owned by institutional investors and hedge funds.

Tempest Therapeutics Company Profile

Tempest Therapeutics, Inc, a clinical-stage oncology company, develops small molecule therapeutics that combine both tumor-targeted and immune-mediated mechanisms to treat various tumors. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, which is in a Phase 1 trial to treat cancer; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial for the treatment of solid tumors.